SOGC COMMITEE OPINIONMissed Hormonal Contraceptives: New Recommendations
REFERENCES (92)
- et al.
The 2002 Canadian contraception study: part 1
J Obstet Gynaecol Can
(2004) - et al.
Estimates of contraceptive failure from the 2002 National Survey of Family Growth
Contraception
(2008) - et al.
Effective use of hormonal contraceptives: Part I: Combined oral contraceptive pills
Contraception
(2006) - et al.
Effective use of hormonal contraceptives: part II: combined hormonal injectables, progestogen-only injectables and contraceptive implants
Contraception
(2006) - et al.
Missed contraceptive pills and the critical pill-free interval
Lancet
(2005) - et al.
Ovarian activity during regular oral contraceptive use
Contraception
(1996) - et al.
Ovarian function during low-dose oral contraceptive use
Contraception
(1995) - et al.
Ultrasound evaluation of ovarian activity under oral contraceptives
Contraception
(1993) - et al.
A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development
Am J Obstet Gynecol
(1992) - et al.
Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
Contraception
(2004 Nov)
comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity
Contraception
Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol
Contraception
Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel
Am J Obstet Gynecol
Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users
Contraception
Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives
Contraception
Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error
Fertil Steril
The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol
Contraception
Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake
Am J Obstet Gynecol
Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation
Am J Obstet Gynecol
The effect of follicular growth and luteal function of “missing the pill”. A comparison between a monophasic and a triphasic combined oral contraceptive
Contraception
The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis
Contraception
Hormonal consequences of “missing the pill”
Contraception
‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills
Contraception
Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill (‘Microgynon 30’) omission
Contraception
Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment
Contraception
Predicting risk of ovulation in new start oral contraceptive users
Obstet Gynecol
Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval
Am J Obstet Gynecol
Greater inhibition of the pituitary—ovarian axis in oral contraceptive regimens with a shortened hormone-free interval
Contraception
Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use
Contraception
Shorter pill-free interval in combined oral contraceptives decreases follicular development
Contraception
Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function
Fertil Steril
Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days
Contraception
Timing of onset of contraceptive effectiveness in Depo-Provera users: part I. Changes in cervical mucus
Fertil Steril
Variability of pharmacokinetic parameters for contraceptive steroids
J Steroid Biochem
Pharmacokinetics of ethynyloestradiol in women for different populations
Contraception
Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications
Am J Obstet Gynecol
Contraceptive failure in the United States
Contraception
Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation
Contraception
Contraceptive efficacy, compliance and beyond: Factors related to satisfaction with once-weekly transdermal compared with oral contraception
Eur J Obstet Gynecol Reprod Biol
Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study
Am J Obstet Gynecol
Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring
Obstet Gynecol
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone
Contraception
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial
Contraception
Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders
Am J Obstet Gynecol
Depo now: preventing unintended pregnancies among adolescents and young adults
J Adolesc Health
Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist
Fertil Steril
Cited by (21)
Intrauterine Contraception: Underestimated and underutilized
2017, Journal of Obstetrics and Gynaecology CanadaNo. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception
2017, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :If EC is indicated and a woman uses UPA-EC rather than LNG-EC, she should wait 5 days before restarting her CHC. She should use a barrier contraceptive method or abstain from intercourse for the first 5 days after taking UPA-EC and for the first 7 days after starting CHC (i.e., when UPA-EC is used and CHC is restarted, back-up contraception and/or abstinence is required for a total of 12 days after UPA-EC ingestion) (see Addendum to the Canadian Consensus On Contraception: Emergency Contraception243). Many women and health care providers have difficulty understanding missed pill instructions.244
No. 329-Canadian Contraception Consensus (Part 4 of 4): Chapter 9 - Combined hormonal contraception
2017, Journal of Obstetrics and Gynaecology CanadaCanadian Contraception Consensus (part 3 of 4): Chapter 8 - Progestin-only contraception
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :Un mode de contraception d’appoint devrait être utilisé pendant 48 heures. Lorsque des relations sexuelles non protégées ont eu lieu, la mise en œuvre d’une contraception d’urgence est recommandée218. Lorsque l’on a recours à une contraception d’urgence faisant appel au lévonorgestrel, la femme devrait recommencer à prendre des PPS le jour suivant et utiliser un mode de contraception d’appoint pendant 48 heures de plus.
Canadian Contraception Consensus (Part 3 of 4): Chapter 8 - Progestin-Only Contraception
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :Back-up contraception should be used for 48 hours. If UPI has occurred, emergency contraception (EC) is recommended.218 In the case of LNG-EC, she should start the POP the next day and use back-up contraception for another 48 hours.
Canadian Contraception Consensus Chapter 3 Emergency Contraception
2015, Journal of Obstetrics and Gynaecology Canada
This committee opinion has been reviewed by the Social and Sexual Issues Committee and reviewed and approved by the Executive of the Society of Obstetricians and Gynaecologists of Canada.
Disclosure statements have been received from all members of the committee.
This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.